Description
HS-20117 is an investigational drug currently being studied by Jiangsu Hansoh Pharmaceutical Co., Ltd. It is being evaluated in early-phase clinical trials (Phase 1) for patients with advanced solid tumors, including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). The trials are primarily focused on patients whose tumors have a specific KRAS G12C mutation. HS-20117 is being tested in combination with other standard anti-cancer therapies, such as chemotherapy (like 5-Fluorouracil, Capecitabine, Oxaliplatin, Leucovorin, Platinum) and other investigational agents (like HS-10370, HS-20093, Adebrelimab). The goal of these early trials is to determine the safety, tolerability, and potential effectiveness of HS-20117 in these patient populations. It is not yet approved for use in CRC or any other cancer.
Mechanism of Action
The specific way HS-20117 works (its mechanism of action) is currently being investigated in clinical trials. It is being studied in combination with other anti-cancer therapies to see if it can improve treatment outcomes in patients with KRAS G12C-mutated advanced solid tumors, including CRC.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.